Abstract-After a chelation treatment, assessment of intake and doses is the primary concern of an internal dosimetrist. Using the urinary excretion data from two actual wound cases encountered at Los Alamos National Laboratory (LANL), this paper discusses several methods that can be used to interpret intakes from the urinary data collected after one or multiple chelation treatments. One of the methods uses only the data assumed to be unaffected by chelation (data collected beyond 100 d after the last treatment). This method, used by many facilities for official dose records, was implemented by employing maximum likelihood analysis and Bayesian analysis methods. The impacts of an improper assumption about the physicochemical behavior of a radioactive material and the importance of the use of a facility-specific biokinetic model when available have also been demonstrated. Another method analyzed both the affected and unaffected urinary data using an empirical urinary excretion model. This method, although case-specific, was useful in determining the actual intakes and the doses averted or the reduction in body burdens due to chelation treatments. This approach was important in determining the enhancement factors, the behavior of the chelate, and other observations that may be pertinent to several DTPA compartmental modeling approaches being conducted by the health physics community. Health Phys. 113(1): 30-40; 2017 
INTRODUCTION
SEVERAL STUDIES have been conducted in the last several decades to develop methods to effectively increase the clearance of actinides such as plutonium from the body. DTPA (diethylenetriaminepenta-acetic acid) is one of the most researched and widely used chelating agents and has been approved by the U.S. Food and Drug Administration (USFDA 2004) . The DTPA binds to plutonium in the body and forms a chelate (Pu-DTPA), the biokinetic property of which dominates that of plutonium. The DTPA increases the urinary clearance of plutonium from the body, effectively decreasing the deposition in the systemic organs. Since the administration of DTPA perturbs the biokinetics of plutonium, systemic models that describe the behavior of "normal" plutonium (e.g., ICRP 1993; Luciani and Polig 2000; Leggett et al. 2005; ) cannot be used to assess the intake from urinary excretion affected by DTPA therapy. Several methods and modeling approaches (e.g., Jech et al. 1972; Hall et al. 1978; La Bone 1994a and b, 2002; Fritsch et al. 2007; James et al. 2007; Bailey et al. 2003; Breustedt et al. 2009 Breustedt et al. , 2010 have been described in the scientific literature on ways to assess the intake and doses after the administration of the DTPA therapy. Despite a long history of the application of DTPA in several accidental exposures, several of these approaches are empirical and case-specific. No consensus approach or model, as those available for the biokinetics of unperturbed plutonium, is available for the behavior of Pu-DTPA.
After a chelation treatment, assessment of intake and doses is one of the primary concerns of an internal dosimetrist of a facility. The objective of this work was to assess the intakes and doses calculated from urinary excretion data collected after the administration of chelation therapy using different methods. The objective was also to provide information on urinary enhancement, the behavior of Pu-DTPA in the human body, and other observations potentially important for several modeling attempts being conducted by the health physics community. The data used in this analysis came from actual wound cases encountered at Los Alamos National Laboratory (LANL).
COLLECTED DATA
The LANL internal dosimetry database contains bioassay data and descriptions of several wound cases that occurred throughout the history of the Laboratory. A query of the database was completed to obtain the wound cases that were chelated at least once after the incident. Wound cases that may have been confounded by significantly larger previous intakes were not included. Wound cases without proper recordings of the times and the number of chelation treatments were also excluded from the analysis. This left the authors with only two chelated wound cases for consideration. The cases have been discussed in detail in Bertelli et al. (2010) ; however, a brief summary is presented here.
Description of wound cases
Case 1. This case involved a
239
Pu intake through a wound on the left index finger, which occurred while working in a glovebox containing Pu metals. The person received an injection of 500 mg Zn-DTPA immediately after the intake and 1 g Ca-DTPA a day after the intake. The person also received 1 g of Zn-DTPA on 2, 3, 4, 5, 6, 8, 9, 10, 11, 15, 17, 22, 24, 29, 31, 44, 52, 58, 66, 78 , and 92 d after the intake. In addition, 1 g Ca-DTPA was administered at 106, 121, 135, 151, and 163 d after the intake. Finally, an injection of 1 g of Ca-DTPA was administered at the person's request on day 590, for a total of 29 chelations.
Case 2. This case, described as Case 3 in Bertelli et al. (2010) , involved deposition of a metallic fragment containing 239 Pu on the right thumb of the worker while working in a glovebox. This case was treated on days 0, 1, 5, and 7 after the incident for a total of four treatments.
Bioassay data
Since at the time LANL had no fixed protocol for when to collect urine samples after a chelation treatment was administered, the samples were collected at various times after the chelation treatments. Most cases contain urinary excretion data for extended periods of time after the chelation treatment. Because it was known that the data collected immediately after the chelation were not suitable for dose assessment purposes using standard biokinetic models, samples were collected around and after 100 d after the last chelation treatment for each case. The database contains urinary excretion data for a period until approximately 3 and 7 y post intake for cases 1 and 2, respectively. Urinary samples were analyzed using either the radiochemical alpha spectrometry (RAS) method or thermal ionization mass spectrometry (TIMS) method (Inkret et al. 1998) . In circumstances when samples were analyzed using both methods, a variance weighted average value was used for the analysis:
where A RAS and A TIMS are the activities measured using RAS and TIMS methods, respectively, and s RAS and s TIMS are the uncertainties associated with the measurements.
MAXIMUM LIKELIHOOD ANALYSIS OF "UNAFFECTED" DATA
It is widely accepted that the chelation treatment affects the urinary excretion data for a period of weeks or months after the cessation of the treatment (e.g., Jech et al. 1972; Schofield and Lynn 1973; Davesne et al. 2016) . Because of the paucity of the data, no conclusions can be made regarding the relationship between the exposure conditions or the forms of the material with the duration of the effect of DTPA on urinary excretion. At LANL, urinary excretion data until 100 days after last DTPA treatment are considered to be "affected. " Jech et al. (1972) proposed exclusion of the urinary excretion data possibly affected by the chelation therapy for the estimation of I eff , the effective intake. This is also the method recommended by the IDEAS General Guidelines to estimate the committed effective dose after chelation treatments (Castellani et al. 2013) .
Several statistical methods are available for fitting of the excretion data (Skrable et al. 1988; IAEA 2004) . One of the most commonly used methods for bioassay data-fitting is the maximum likelihood method (Castellani et al. 2013 ). This method is employed by several internal dosimetry software programs, such as Integrated Modules for Bioassay Analysis (IMBA) (Birchall et al. 2007 ) and Activity and Internal Dose Estimates (AIDE) (Bertelli et al. 2008) . This method minimizes the value of chi-square, given as:
and the estimate of the intake is given as (Castellani et al. 2013 ):
where M i is the value of the ith measurement, m(t i ) is the intake retention fraction or excretion fraction associated with the ith measurement, I i is the intake calculated from the ith measurement and is given as I i = M i /m(t i ), and SF i is the scattering factor associated with the ith measurement.
For the behavior of a radionuclide after a wound intake, the NCRP 156 wound model (NCRP 2007) proposes a multi-compartmental biokinetic model consisting of five compartments that lead to the systemic uptake into the blood or clearance into the lymph nodes (Fig. 1) . A generic wound model consists of five compartments: Soluble; Colloidal and Intermediate States (CIS); Particles, Aggregates and Bound States (PABS); Trapped Particles and Aggregates (TPA); and Fragments, which were conceived in order to describe the behavior of both soluble and insoluble radioactive materials regardless of the initial physical and chemical state. The category "soluble" is further divided into retention classes of weak, moderate, strong and avid categories. The transfer of radioactive materials is described by first-order kinetics, and the transfer rates between the compartments are given in Table 1 .
The wound model can be combined with Leggett's (Leggett et al. 2005 ) systemic model ( Fig. 1 ) to evaluate the urinary data and assess the intake and to calculate the committed doses to organs and tissues (NCRP 2006; Guilmette et al. 2007; Doerfel et al. 2012) . The effective intakes were estimated using maximum likelihood analysis of the urinary excretion data not affected by chelation; i.e., data collected at least 100 d post the last chelation treatment. Since the actual chemistry and solubility of the material was unknown, several wound models were used in the analysis. Two wound models specific to previous wound cases at LANL (Miller 2010) were also used in the analysis (Table 1 ). In addition, analyses were also done assuming straight input into the blood (injection).
The SF recommended by the IDEAS Guidelines (Castellani et al. 2013 ) (i.e., 1.1 for true 24-h urine and 1.6 for simulated 24-h urine) were used in the analysis. These values were based on values of SF B (i.e., scattering factor due to Type B uncertainties) with an assumption that SF A (i.e., scattering factor due to Type A uncertainties) has little influence on the overall SF calculation (Castellani et al. 2013) . The results of the maximum likelihood analysis of the urinary excretion data using different wound models combined with the Leggett's systemic model are given in Table 2 . The estimates of the effective intake (I eff ) depended significantly on the biokinetic model used for the analysis. In both cases, minimum chi-square was obtained when the "LANL soluble" wound model was used. This was expected because the solubility and chemistry of the plutonium to which the subjects were exposed may have been very similar to the case from which the "LANL soluble" model was derived. The maximum likelihood analysis of the urinary excretion data using the "best" model is shown in Fig. 2 . Hall et al. (1978) described an empirical urinary excretion model as a method to assess intake for the evaluation of intakes using data influenced by chelation. This method has been reviewed by LaBone (1994a LaBone ( , 1994b LaBone ( and 2002 , and it has been applied to several intake cases involving chelation. A compact description of Hall's method using the discussion and the nomenclature similar to LaBone (2002) is presented in eqns (4) to (6): The models for soluble radionuclides assume direct injection into the "Soluble" compartment.
EVALUATION OF DATA AFFECTED BY CHELATION
b
The models for colloids, particles and fragments assume direct injection into "CIS", "PABS" and "Fragment" compartments respectively.
c These models are the default wound models described in NCRP Report 156 (NCRP 2007) . These models are based on fitting data from two specific cases at LANL (Miller 2010 ).
e
The LANL bioassay analysis program, and thus this work, uses these models, in addition to the immediate injection model, for the analysis of the Pu-contaminated wounds. where: e exp = daily urinary excretion of plutonium expected at time t > t N I = actual intake; i u (t) = the fraction of intake expected to be in a 24-hour urine sample (unperturbed); N = number of chelation treatments; K j = fraction of intake that is expected to be removed by the jth chelation; t i = time (number of days after intake) when chelation was administered; E = the enhancement factor; i c (t − t j ) = incremental urinary excretion function for the chelate; C 1 ,C 2 = coefficients for rapid and slow removal of the chelate; and h 1 , h 2 = short-and long-term retention half-lives of the chelate.
At the time of the publication of Hall's model, complex biokinetic models like those of today were not available. Hall et al. (1978 ) used Durbin's expression (1972 to estimate I u (t), the urinary excretion rates unaffected by chelation treatment. LaBone (1994b) , in his discussion of Hall's model, used Jones's equation (Jones 1985) with Fig. 2 . The fit of the "unaffected" urinary excretion data (represented by filled circles) using maximum likelihood analysis and "LANL Soluble" model. an assumption of slow and rapid feed intakes to calculate I u (t) from a plutonium intake by wound. Today, complex biokinetic models (e.g., ICRP 1993; Luciani and Polig 2000; Leggett et al. 2005 ) are available to compute the urinary excretion rates from Pu intakes.
The parameters in the Hall's model were calculated using an enhancement factor (E) of 78 based on the observed values in workers at the Savannah River Plant (Hall et al. 1978) . LaBone used E values of 18.5 to 77 through trial and error to get the best fit to the observed urinary excretion rates (LaBone 1994b (LaBone , 2002 . A review of the literature shows the enhancement factors for Pu-DTPA may range from approximately 1 to 130 (Norwood 1962; Anderson et al. 1970; Jech et al. 1972; Jolly et al. 1972; Parker 1973; Schofield and Lynn 1973; Piechowski et al. 1989; LaBone et al. 1994a and b; Bailey et al. 2003; James et al. 2008; Bertelli et al. 2010; Davesne et al. 2016) . The efficacy of chelation also depends on the chemical and physical characteristics of the compound at the time of DTPA administration (NCRP 2006; Voelz 2001 ). For example, DTPA is essentially nonefficient for highly insoluble compounds such as highfired oxide (Voelz 2001) .
Since an incorrect assumption about the enhancement factor may have a significant impact on the estimation of the intake and the effective intake, different combinations of the enhancement factors (E) and the parameters in eqn (6) were used to obtain a fit to the observed values. The short-term retention half-life of the chelate (h 1 ) of 0.1 through 1 d; and a relatively longer term retention half-life of the chelate (h 2 ) of 1 through 10 were used in analysis. This was in accordance with the known biokinetic behavior of the chelate-the biological half-life of the chelate is very short, with more than 90% being excreted within a day (e.g., Stather et al. 1983; Durbin et al. 1997 ) and the urinary excretion enhancement effect lasting anywhere from a few weeks up to a 100 d post chelation (e.g., Schofield and Lynn 1973; Jech et al. 1972; Davesne et al. 2016) . The combination of the parameters that produced the best fit of the data for a given case was used to assess the intake for the case. The intake for each case was calculated using the maximum likelihood method described above. The calculated intake along with the parameters used in the calculation are given in Table 3 . The modeled effects of DTPA on urinary excretion were plotted against the observed urinary excretion data in Fig. 3 .
THE BAYESIAN APPROACH
The intake and dose estimates for LANL employees are calculated using the Bayesian Markov-Chain Monte Carlo Internal Dosimetry Code (Version IDT.0E, 2012). The methods have been previously described in several publications (Miller et al. 1999 (Miller et al. , 2001 (Miller et al. , 2002 (Miller et al. , 2003 . In this method, instead of assuming that the intake is exclusively of one form or solubility, an equal probability is assigned to several biokinetic models (Leggett's systemic model in addition to the wound models discussed earlier), which constitute the priors. The software computes the expected values of the intake and the effective doses (along with the 95% confidence interval) as well as the posterior probability for each type of the model. The results of the Bayesian analysis of the urinary excretion data from cases 1 and 2 not affected by the chelation treatment are given in Table 4 . The results of the Bayesian analysis of the bioassay data from both cases indicated a predominance of the "LANL soluble" model and "direct injection" model. The contributions of the NCRP 156 avid, colloid, and particle models were null for each case (Table 4 ). This analysis was also supported by the maximum likelihood analysis of the data. Minimum chisquares were obtained when the analysis was done using the "LANL soluble" model, followed by the model for direct injection into the blood (Table 2) .
Finally, it is important to note that the intakes estimated from the Bayesian analysis of "unaffected" urinary excretion data presented in Bertelli et al. (2010) are different than those presented in this paper. As an example, the results for Case 2 are compared in Table 5 . The analysis of Case 2 presented in Bertelli et al. (2010) was a result of the follow-up of the case up to a period of only 185 d, but at the time of the current analysis, the bioassay data until almost 7 y after the intake were available. Because more bioassay measurements were available, the Bayesian analysis resulted in different posterior probabilities for each wound model. For example, the contributions of the "LANL Soluble" model increased from 0.171 to 0.645; and the contributions of NCRP 156 Avid, NCRP 156 Colloid, NCRP 156 Particles and "LANL Colloid" models decreased to zero (Table 5) . The increase in the number of data points resulted in a smaller intake estimate and a tighter confidence interval for the intake. 
DISCUSSION
The results of three different approaches of assessing intake and doses using the urinary excretion data after chelation treatment are given in Table 6 .
The differences between the intakes estimated using Bayesian analysis and Hall's method were approximately 15% and 16% for cases 1 and 2, respectively. The maximum likelihood analysis of urine data in both cases resulted in an estimate of intake approximately twice as large as that using Bayesian analysis. This was because of the differences in the assumption of models-the maximum likelihood analysis used a single model ("LANL Soluble") to estimate the intake, while it was known from the Bayesian analysis that a significant contribution as a "direct injection" also existed. Moreover, for case 1, the associated p-value was less than 0.05, meaning that the model did not adequately fit the data. Maximum likelihood analysis in such cases requires optimization of parameters to obtain adequate fits, but such analysis was beyond the scope of the objectives of this paper.
Hall's method is largely empirical-its application requires assumptions about the enhancement factor and the behavior of the chelate, and thus it cannot be used to make conclusions about the general effects of the DTPA treatments. For example, enhancement factors of 12.5 and 20.5 were obtained for the cases described in this paper. Nevertheless, application of this method is considered important primarily because it allows us to calculate the actual intakes had there been no chelation. This method can be used to obtain estimates of intake when managers or regulators require an early order-of-magnitude estimate of the intake. While other methods require a waiting time for the effects of chelation to subside, this method can be used directly to analyze the "affected" data.
In addition, Hall's method also enables the calculation of doses averted due to treatments and determination of the efficacy of chelation treatment. For example, the dose averted due to chelation for case 1 (29 chelation treatments) was approximately 166 mSv, and that for case 2 (four chelation treatments) was 10 mSv (Table 5 ). Approximately 86% of the body burden was removed by 29 chelations for case 1, and 66% was removed by four chelations for case 2 (Table 6 ). This is comparable to the results for several 239 Pu nitrate wound cases reviewed in a technical report by IAEA-the reduction in body burdens for cases 14, 15, 16, and 51 reviewed in the document were approximately 60%, 60%, 50%, and 40-60% due to approximately 20, 60, 13, and 6 treatments, respectively (IAEA 1978) .
The fraction of intake removed by each successive chelation for case 1 is shown in Fig. 4 . The first and second chelations removed approximately 30% and 17% of the actual intake, respectively, whereas the successive chelations removed an increasingly lower amount of Pu. The fraction removed by a chelation treatment depends on the number of prior treatments administered because the "apparent intake" decreases with each removal of activity due to chelation. In addition, the fraction also depends on the time after intake that the chelation was administered-the effectiveness of treatment diminishes at longer times after the intake (NCRP 2007) .
It is important to note the significant enhancement in urinary excretion when chelation treatments were administered several months after the intake (Fig. 3) . Such enhancement in the urinary excretion may not be completely explained by the binding action of the DTPA with the near-negligible amount of Pu available in blood or the extracellular fluid alone, especially after several previous chelation treatments. This observation lends support to the hypothesis that DTPA may decorporate plutonium residing in intracellular sites as well Gremy et al. 2016) . In fact, the liver has been long known to be a site of DTPA influence in animals and humans (e.g., Bhattacharyya et al. 1978; Roedler et al. 1989; Bhattacharyya and Peterson 1979; Breitenstein and Palmer 1989; James et al. 2007 ). This observation is particularly important for compartmental modeling approaches, and several biokinetic modeling approaches for Pu-DTPA have recognized this behavior of DTPA (e.g., Fritsch et al. 2007 Fritsch et al. , 2010 Breustedt et al. 2009; . In addition, DTPA may also directly decorporate Pu from bone surfaces and bone marrow as some studies have indicated (James and Taylor 1971; James et al. 2007) . A much simpler method to interpret the urinary excretion data is to simply divide the urinary excretion rate by the enhancement factor and use the intake retention fractions obtained from standard biokinetic models or a combination thereof. Because enhancement factors have been reported from 1 to 130 in the literature, and the choice of an enhancement factor has a significant impact on the estimation of the intake and dose and possibly the actions taken after the intake (Davesne et al. 2016) , the intake and dose estimated using an enhancement factor has a large uncertainty and should be treated as such. For example, an assumption of an enhancement factor of 50-as recommended by the French Society of Occupational Medicine (SFMT 2011, cited in Davesne et al. 2016 )-would have underestimated the intake and the dose for both of the cases presented here.
Many facilities, for the official dose records, discard the data collected during the treatment period and use only the data assumed to be unaffected by chelation. As shown in this paper, this can be done using either the maximum likelihood analysis or the Bayesian approach. Use of a proper biokinetic model is important when assessing intakes and doses, as improper assumptions about the physicochemical behavior of involved radioactive material can lead to inaccurate estimates. This can be done by assessing the goodness of fit when using the maximum likelihood analysis method or by assigning a prior distribution for appropriate biokinetic models when using Bayesian analysis. When available, facility-specific information and models should be used when performing such analysis, as such models may reflect the behavior of the materials encountered in the facility more appropriately than the generic biokinetic models.
CONCLUSION AND FUTURE WORK
Three different approaches were successfully applied to LANL bioassay data from plutonium contaminated wounds. These methods were useful to infer intakes, effective intakes, and doses from the urinary excretion data after a wound intake, and they provide insight into enhancement factors and the behavior of the chelate that can be useful for Pu-DTPA modeling. While maximum likelihood and Bayesian analysis of the "unaffected" data should be used for official intake and dose estimates, application of an empirical approach to the "affected" data may also provide reliable estimates of the order of magnitude of the actual intakes. These analyses also indicated the importance of choice of the proper model when using maximum likelihood analysis.
While the biokinetic behavior of plutonium is considered to be well understood, that of Pu-DTPA is still largely empirical. However, the literature shows that the health physics community has recently been moving toward the compartmental modeling of the Pu-DTPA (e.g., Bailey et al. 2003; Fritsch et al. 2007 Fritsch et al. , 2010 James et al. 2008; Breustedt et al. 2009 Breustedt et al. , 2010 . The LANL internal dosimetry dataset consists of the bioassay data over a period of several decades of its operation that will prove useful for such modeling. The next step is to attempt to physiologically model the effect of multiple DTPA treatments in the excretion of plutonium based on the available data and the findings of this paper.
